Update on Cancer Treatment Research: April – 2019News

Autophagy and its potent modulators from phytochemicals in cancer treatment

Autophagy may be a omnipresent catabolic method by that broken or harmful living thing parts are delivered to the lysosomes for self-digestion and usage. it’s crucial in cancer treatment. Therapy-induced autophagy preponderantly acts as a pro-survival mechanism, however progressive autophagy will cause non-apoptotic necrobiosis, additionally called autophagic necrobiosis. Plants or herbs contain varied natural compounds that are wide utilized in the treatment of the many forms of malignancies. rising proof indicates that phytochemicals targeting the autophagic pathway are promising agents for cancer treatment. However, these compounds play completely different roles in autophagy. during this review, we have a tendency to mentioned the role of autophagy in cancer development and medical aid, and focussed on elucidating the anti-cancer activities of autophagic modulators, particularly phytochemicals. Notably, we have a tendency to represented a completely unique premise that the dynamic role of phytochemicals ought to be evaluated in regulation of autophagy in cancer. [1]

HDMX inhibitors and their use for cancer treatment

The present invention provides for novel acridine-like category of compounds that have incontestible potency in treating cancer. The compounds of this invention have incontestible effectuality in binding to and antagonizing the activity of the p53 represser, HDMX. Once administered to a cell, the compounds of this invention bind HDMX, thereby permitting p53 to induce programmed cell death of the cancerous cell. a mixture of this category of compounds together with Nutlin3 provides a unique approach to treat cancers. [2]

Social Support, Insomnia, and Adherence to Cognitive Behavioral Therapy for Insomnia After Cancer Treatment

Objective/Background: whereas cognitive-behavioral medical care for sleep disorder (CBT-I) has been shown to be efficacious in treating cancer survivors’ insomnia, 30–60% of people have issue adhering to intervention elements. Psychosocial predictors of adherence and response to CBT-I, like social support, haven’t been examined in intervention studies for cancer survivors. Participants: knowledge from a irregular placebo-controlled two x 2 trial of CBT-I and armodafinil (a wakefulness promoting agent) were wont to assess adherence. 96 cancer survivors participated within the trial (mean age fifty six, 86% female, sixty eight breast cancer). Methods: CBT-I and armodafinil were administered over the course of seven weeks, and participants were assessed at baseline, throughout intervention, postintervention, and at a three-month follow-up. Social support was assessed employing a purposeful Assessment of Chronic sickness medical care subscale, sleep disorder severity was assessed victimisation the sleep disorder Severity Index, and adherence was measured supported CBT-I sleep prescriptions. Results: At baseline, social support was negatively correlate with sleep disorder severity (r = –0.30, p = 0.002) and associations between social support, CBT-I, and sleep disorder were maintained through the three-month follow-up. Social support was completely related to adherence to CBT-I throughout intervention weeks three, 4, and 5, and with overall intervention adherence. At postintervention, each social support and treatment with CBT-I severally foreseen attenuate sleep disorder severity (p < zero.01) once dominant for baseline sleep disorder severity. Conclusions: Higher social support is related to higher intervention adherence and improved sleep freelance of CBT-I. further analysis is required to work out whether or not social support will be leveraged to boost adherence and response to CBT-I. [3]

Targeting cancer vulnerabilities with high-dose vitamin C

Over the past century, the notion that water-soluble vitamin is accustomed treat cancer has generated abundant disputation. However, new information concerning the pharmacokinetic properties of water-soluble vitamin and up to date high-profile diagnosis studies have revived interest within the utilization of high-dose vitamin C for cancer treatment. Studies have shown that pharmacologic water-soluble vitamin targets several of the mechanisms that cancer cells utilize for his or her survival and growth. during this Opinion article, we have a tendency to discuss however water-soluble vitamin will target 3 vulnerabilities several cancer cells share: oxidation-reduction imbalance, epigenetic reprogramming and oxygen-sensing regulation. though the mechanisms and prophetical biomarkers that we have a tendency to discuss must be valid in well-controlled clinical trials, these new discoveries concerning the antitumour properties of water-soluble vitamin are promising to assist establish patient populations which will profit the foremost from high-dose vitamin C medical care, developing effective combination methods and up the style of future water-soluble vitamin clinical trials for numerous kinds of cancer. [4]

Periodic Catatonia after Thyroid Cancer

We are presenting the case of a fifty two year previous feminine with 3 distinct episodes of clinical deterioration over a twenty year amount once thyroid cancer treatment. the primary decrease in functioning happened once the identification of thyroid cancer, leading to the patient not achieving her PhD thesis. The second deterioration happened 10 years later once she bestowed with psychotic symptoms and therefore the symptoms of eating disorder. The last amount of decay occurred one year before this hospitalization. throughout that point the patient worsened to the purpose wherever she became bedbound and captivated with a PEG tube for feeding. Once hospitalized, the patient had partial response to Ativan (27 mg a day) so dextroamphetamine was another with positive response. The addition of memantine helped with the residual symptoms. The PEG tube was finally able to be removed and therefore the patient was discharged zero in stable condition. [5]


[1] Sun, C.Y., Zhang, Q.Y., Zheng, G.J. and Feng, B., 2019. Autophagy and its potent modulators from phytochemicals in cancer treatment. Cancer Chemotherapy and Pharmacology, 83(1), pp.17-26. (Web Link)

[2] Wald, D., Agarwal, M., Xia, Z., Karan, G. and Gundluru, M., MiRx Pharmaceuticals LLC, 2019. HDMX inhibitors and their use for cancer treatment. U.S. Patent Application 10/183,912. (Web Link)

[3] Kamen, C., Garland, S.N., Heckler, C.E., Peoples, A.R., Kleckner, I.R., Cole, C.L., Perlis, M.L., Morrow, G.R., Mustian, K.M. and Roscoe, J.A., 2019. Social support, insomnia, and adherence to cognitive behavioral therapy for insomnia after cancer treatment. Behavioral sleep medicine, 17(1), pp.70-80. (Web Link)

[4] Targeting cancer vulnerabilities with high-dose vitamin C

Bryan Ngo, Justin M. Van Riper, Lewis C. Cantley & Jihye Yun

Nature Reviews Cancer (2019) (Web Link)

[5] Aragon, D., Humphries, P., Heare, M. and Bota, R. G. (2016) “Periodic Catatonia after Thyroid Cancer”, Journal of Advances in Medicine and Medical Research, 14(5), pp. 1-4. doi: 10.9734/BJMMR/2016/24784. (Web Link)

Leave a Reply

Your email address will not be published. Required fields are marked *